Do analysts prefer APM or QUCY?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aptorum Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has stronger earnings and valuation, APM or QUCY?

Aptorum Group has higher earnings, but lower revenue than Mainz Biomed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aptorum Group $430K 9.86 -$1.36M N/A N/A Mainz Biomed $540K 31.49 -$16.21M -$47.60 N/A

Is APM or QUCY more profitable?

Company Net Margins Return on Equity Return on Assets Aptorum Group N/A N/A N/A Mainz Biomed N/A N/A N/A

Does the media prefer APM or QUCY?

In the previous week, Mainz Biomed had 2 more articles in the media than Aptorum Group. MarketBeat recorded 5 mentions for Mainz Biomed and 3 mentions for Aptorum Group. Mainz Biomed's average media sentiment score of 0.25 beat Aptorum Group's score of -0.67 indicating that Mainz Biomed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aptorum Group 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Mainz Biomed 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend APM or FTH?

Sensei Biotherapeutics has a consensus price target of $54.00, indicating a potential upside of 91.56%. Given Sensei Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Sensei Biotherapeutics is more favorable than Aptorum Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aptorum Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Sensei Biotherapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78

Which has stronger earnings and valuation, APM or FTH?

Aptorum Group has higher revenue and earnings than Sensei Biotherapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aptorum Group $430K 9.86 -$1.36M N/A N/A Sensei Biotherapeutics N/A N/A -$21.08M -$142.72 N/A

Is APM or FTH more profitable?

Aptorum Group's return on equity of 0.00% beat Sensei Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aptorum Group N/A N/A N/A Sensei Biotherapeutics N/A -83.59% -256.50%

Does the media refer more to APM or FTH?

In the previous week, Sensei Biotherapeutics had 2 more articles in the media than Aptorum Group. MarketBeat recorded 5 mentions for Sensei Biotherapeutics and 3 mentions for Aptorum Group. Sensei Biotherapeutics' average media sentiment score of 0.20 beat Aptorum Group's score of -0.67 indicating that Sensei Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aptorum Group 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Sensei Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer APM or NEUP?

Neuphoria Therapeutics has a consensus target price of $21.00, indicating a potential upside of 536.36%. Given Neuphoria Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Neuphoria Therapeutics is more favorable than Aptorum Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aptorum Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Neuphoria Therapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings and valuation, APM or NEUP?

Neuphoria Therapeutics has higher revenue and earnings than Aptorum Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aptorum Group $430K 9.86 -$1.36M N/A N/A Neuphoria Therapeutics $15.65M 1.14 -$370K -$11.06 N/A

Is APM or NEUP more profitable?

Aptorum Group's return on equity of 0.00% beat Neuphoria Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aptorum Group N/A N/A N/A Neuphoria Therapeutics N/A -76.93% -54.76%

Which has stronger valuation & earnings, ALLR or APM?

Aptorum Group has higher revenue and earnings than Allarity Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Allarity Therapeutics $320K 58.17 -$11.23M -$0.72 N/A Aptorum Group $430K 9.86 -$1.36M N/A N/A

Is ALLR or APM more profitable?

Aptorum Group's return on equity of 0.00% beat Allarity Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Allarity Therapeutics N/A -109.94% -47.27% Aptorum Group N/A N/A N/A

Do analysts rate APM or RKTO?

Rocket One Inc. Common Stock has a consensus target price of $5.00, indicating a potential upside of 500.17%. Given Rocket One Inc. Common Stock's stronger consensus rating and higher possible upside, analysts clearly believe Rocket One Inc. Common Stock is more favorable than Aptorum Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aptorum Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Rocket One Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings and valuation, APM or RKTO?

Aptorum Group has higher revenue and earnings than Rocket One Inc. Common Stock. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aptorum Group $430K 9.86 -$1.36M N/A N/A Rocket One Inc. Common Stock N/A N/A -$12.47M -$0.80 N/A

Is APM or RKTO more profitable?

Aptorum Group's return on equity of 0.00% beat Rocket One Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Aptorum Group N/A N/A N/A Rocket One Inc. Common Stock N/A -165.25% -143.61%

Does the media favor APM or RKTO?

In the previous week, Aptorum Group had 2 more articles in the media than Rocket One Inc. Common Stock. MarketBeat recorded 3 mentions for Aptorum Group and 1 mentions for Rocket One Inc. Common Stock. Rocket One Inc. Common Stock's average media sentiment score of 1.08 beat Aptorum Group's score of -0.67 indicating that Rocket One Inc. Common Stock is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aptorum Group 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Rocket One Inc. Common Stock 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Aptorum Group (APM) Competitors

$0.67 -0.03 (-4.57%)

Closing price 07/17/2026 07:46 PM Eastern

Extended Trading

$0.67 0.00 (0.00%)

As of 07/17/2026 07:46 PM Eastern

Compare

APM vs. QUCY, SNSE, NEUP, ALLR, and RKTO

Should you buy Aptorum Group stock or one of its competitors? MarketBeat compares Aptorum Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aptorum Group include Mainz Biomed (QUCY), Sensei Biotherapeutics (SNSE), Neuphoria Therapeutics (NEUP), Allarity Therapeutics (ALLR), and Rocket One Inc. Common Stock (RKTO). These companies are all part of the "pharmaceutical products" industry.

How does Aptorum Group compare to Mainz Biomed?

Aptorum Group (NASDAQ:APM) and Mainz Biomed (NASDAQ:QUCY) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

3.8% of Aptorum Group shares are owned by institutional investors. 64.0% of Aptorum Group shares are owned by company insiders. Comparatively, 3.1% of Mainz Biomed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
Aptorum Group	N/A	N/A	N/A
Mainz Biomed	N/A	N/A	N/A

Aptorum Group has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market. Comparatively, Mainz Biomed has a beta of 2.28, indicating that its stock price is 128% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptorum Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Aptorum Group has higher earnings, but lower revenue than Mainz Biomed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptorum Group	$430K	9.86	-$1.36M	N/A	N/A
Mainz Biomed	$540K	31.49	-$16.21M	-$47.60	N/A

In the previous week, Mainz Biomed had 2 more articles in the media than Aptorum Group. MarketBeat recorded 5 mentions for Mainz Biomed and 3 mentions for Aptorum Group. Mainz Biomed's average media sentiment score of 0.25 beat Aptorum Group's score of -0.67 indicating that Mainz Biomed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aptorum Group	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Mainz Biomed	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Mainz Biomed beats Aptorum Group on 6 of the 9 factors compared between the two stocks.

How does Aptorum Group compare to Sensei Biotherapeutics?

Aptorum Group (NASDAQ:APM) and Sensei Biotherapeutics (NASDAQ:FTH) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.

3.8% of Aptorum Group shares are owned by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are owned by institutional investors. 64.0% of Aptorum Group shares are owned by company insiders. Comparatively, 7.0% of Sensei Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Aptorum Group's return on equity of 0.00% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aptorum Group	N/A	N/A	N/A
Sensei Biotherapeutics	N/A	-83.59%	-256.50%

Sensei Biotherapeutics has a consensus price target of $54.00, indicating a potential upside of 91.56%. Given Sensei Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Sensei Biotherapeutics is more favorable than Aptorum Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptorum Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sensei Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Aptorum Group has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market. Comparatively, Sensei Biotherapeutics has a beta of -0.26, suggesting that its share price is 126% less volatile than the broader market.

Aptorum Group has higher revenue and earnings than Sensei Biotherapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptorum Group	$430K	9.86	-$1.36M	N/A	N/A
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$142.72	N/A

In the previous week, Sensei Biotherapeutics had 2 more articles in the media than Aptorum Group. MarketBeat recorded 5 mentions for Sensei Biotherapeutics and 3 mentions for Aptorum Group. Sensei Biotherapeutics' average media sentiment score of 0.20 beat Aptorum Group's score of -0.67 indicating that Sensei Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aptorum Group	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Sensei Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Sensei Biotherapeutics beats Aptorum Group on 7 of the 13 factors compared between the two stocks.

How does Aptorum Group compare to Neuphoria Therapeutics?

Aptorum Group (NASDAQ:APM) and Neuphoria Therapeutics (NASDAQ:NEUP) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, media sentiment and analyst recommendations.

3.8% of Aptorum Group shares are owned by institutional investors. Comparatively, 15.9% of Neuphoria Therapeutics shares are owned by institutional investors. 64.0% of Aptorum Group shares are owned by insiders. Comparatively, 1.5% of Neuphoria Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Aptorum Group has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market. Comparatively, Neuphoria Therapeutics has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market.

In the previous week, Aptorum Group had 3 more articles in the media than Neuphoria Therapeutics. MarketBeat recorded 3 mentions for Aptorum Group and 0 mentions for Neuphoria Therapeutics. Neuphoria Therapeutics' average media sentiment score of 0.00 beat Aptorum Group's score of -0.67 indicating that Neuphoria Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Aptorum Group	Negative
Neuphoria Therapeutics	Neutral

Aptorum Group's return on equity of 0.00% beat Neuphoria Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aptorum Group	N/A	N/A	N/A
Neuphoria Therapeutics	N/A	-76.93%	-54.76%

Neuphoria Therapeutics has higher revenue and earnings than Aptorum Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptorum Group	$430K	9.86	-$1.36M	N/A	N/A
Neuphoria Therapeutics	$15.65M	1.14	-$370K	-$11.06	N/A

Neuphoria Therapeutics has a consensus target price of $21.00, indicating a potential upside of 536.36%. Given Neuphoria Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Neuphoria Therapeutics is more favorable than Aptorum Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptorum Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Neuphoria Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Neuphoria Therapeutics beats Aptorum Group on 8 of the 13 factors compared between the two stocks.

How does Aptorum Group compare to Allarity Therapeutics?

Allarity Therapeutics (NASDAQ:ALLR) and Aptorum Group (NASDAQ:APM) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, media sentiment, profitability, risk, dividends, earnings and institutional ownership.

Aptorum Group's return on equity of 0.00% beat Allarity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allarity Therapeutics	N/A	-109.94%	-47.27%
Aptorum Group	N/A	N/A	N/A

11.5% of Allarity Therapeutics shares are owned by institutional investors. Comparatively, 3.8% of Aptorum Group shares are owned by institutional investors. 0.2% of Allarity Therapeutics shares are owned by company insiders. Comparatively, 64.0% of Aptorum Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Aptorum Group has higher revenue and earnings than Allarity Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allarity Therapeutics	$320K	58.17	-$11.23M	-$0.72	N/A
Aptorum Group	$430K	9.86	-$1.36M	N/A	N/A

Allarity Therapeutics has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market. Comparatively, Aptorum Group has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market.

Allarity Therapeutics presently has a consensus price target of $10.25, indicating a potential upside of 776.07%. Given Allarity Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Allarity Therapeutics is more favorable than Aptorum Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aptorum Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Aptorum Group had 3 more articles in the media than Allarity Therapeutics. MarketBeat recorded 3 mentions for Aptorum Group and 0 mentions for Allarity Therapeutics. Allarity Therapeutics' average media sentiment score of 0.00 beat Aptorum Group's score of -0.67 indicating that Allarity Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Allarity Therapeutics	Neutral
Aptorum Group	Negative

Summary

Allarity Therapeutics beats Aptorum Group on 7 of the 13 factors compared between the two stocks.

How does Aptorum Group compare to Rocket One Inc. Common Stock?

Aptorum Group (NASDAQ:APM) and Rocket One Inc. Common Stock (NASDAQ:RKTO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

Rocket One Inc. Common Stock has a consensus target price of $5.00, indicating a potential upside of 500.17%. Given Rocket One Inc. Common Stock's stronger consensus rating and higher possible upside, analysts clearly believe Rocket One Inc. Common Stock is more favorable than Aptorum Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptorum Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Rocket One Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

3.8% of Aptorum Group shares are owned by institutional investors. Comparatively, 7.1% of Rocket One Inc. Common Stock shares are owned by institutional investors. 64.0% of Aptorum Group shares are owned by insiders. Comparatively, 6.9% of Rocket One Inc. Common Stock shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Aptorum Group has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market. Comparatively, Rocket One Inc. Common Stock has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market.

Aptorum Group has higher revenue and earnings than Rocket One Inc. Common Stock.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptorum Group	$430K	9.86	-$1.36M	N/A	N/A
Rocket One Inc. Common Stock	N/A	N/A	-$12.47M	-$0.80	N/A

Aptorum Group's return on equity of 0.00% beat Rocket One Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aptorum Group	N/A	N/A	N/A
Rocket One Inc. Common Stock	N/A	-165.25%	-143.61%

In the previous week, Aptorum Group had 2 more articles in the media than Rocket One Inc. Common Stock. MarketBeat recorded 3 mentions for Aptorum Group and 1 mentions for Rocket One Inc. Common Stock. Rocket One Inc. Common Stock's average media sentiment score of 1.08 beat Aptorum Group's score of -0.67 indicating that Rocket One Inc. Common Stock is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aptorum Group	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Rocket One Inc. Common Stock	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Aptorum Group and Rocket One Inc. Common Stock tied by winning 6 of the 12 factors compared between the two stocks.

Get Aptorum Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

APM vs. The Competition

Export

Metric	Aptorum Group	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.44M	$3.07B	$6.89B	$12.28B
Dividend Yield	N/A	2.05%	2.67%	9.39%
P/E Ratio	N/A	20.20	27.07	23.95
Price / Sales	9.86	340.68	515.05	90.33
Price / Cash	N/A	27.11	26.68	47.25
Price / Book	0.31	4.20	10.62	6.14
Net Income	-$1.36M	$65.94M	$3.60B	$331.74M
7 Day Performance	-91.80%	-3.05%	-1.26%	-1.82%
1 Month Performance	-91.97%	-1.30%	1.07%	-1.45%
1 Year Performance	-96.18%	15.22%	23.63%	16.32%

Aptorum Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
APM Aptorum Group	0.8894 of 5 stars	$0.67 -4.6%	N/A	-95.9%	$4.44M	$430K	N/A	30	High Trading Volume
QUCY Mainz Biomed	0.4589 of 5 stars	$1.33 -1.1%	N/A	N/A	$19.42M	$540K	N/A	30
SNSE Sensei Biotherapeutics	N/A	$14.15 +2.1%	$48.00 +239.3%	N/A	$18.98M	N/A	N/A	40	Gap Up High Trading Volume
NEUP Neuphoria Therapeutics	3.1981 of 5 stars	$3.45 -3.9%	$21.00 +508.9%	-55.7%	$18.63M	$15.65M	N/A	N/A
ALLR Allarity Therapeutics	1.808 of 5 stars	$1.16 +2.7%	$10.25 +783.6%	+17.4%	$18.46M	$320K	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:APM) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aptorum Group (APM) Competitors

APM vs. QUCY, SNSE, NEUP, ALLR, and RKTO

How does Aptorum Group compare to Mainz Biomed?

Summary

How does Aptorum Group compare to Sensei Biotherapeutics?

Summary

How does Aptorum Group compare to Neuphoria Therapeutics?

Summary

How does Aptorum Group compare to Allarity Therapeutics?

Summary

How does Aptorum Group compare to Rocket One Inc. Common Stock?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APM vs. The Competition

Aptorum Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aptorum Group (APM) Competitors

APM vs. QUCY, SNSE, NEUP, ALLR, and RKTO

How does Aptorum Group compare to Mainz Biomed?

Do insiders and institutionals hold more shares of APM or QUCY?

Is APM or QUCY more profitable?

Which has more risk and volatility, APM or QUCY?

Do analysts prefer APM or QUCY?

Which has stronger earnings and valuation, APM or QUCY?

Does the media prefer APM or QUCY?

Summary

How does Aptorum Group compare to Sensei Biotherapeutics?

Do institutionals & insiders have more ownership in APM or FTH?

Is APM or FTH more profitable?

Do analysts recommend APM or FTH?

Which has more risk & volatility, APM or FTH?

Which has stronger earnings and valuation, APM or FTH?

Does the media refer more to APM or FTH?

Summary

How does Aptorum Group compare to Neuphoria Therapeutics?

Do insiders and institutionals believe in APM or NEUP?

Which has more risk and volatility, APM or NEUP?

Does the media refer more to APM or NEUP?

Is APM or NEUP more profitable?

Which has stronger earnings and valuation, APM or NEUP?

Do analysts prefer APM or NEUP?

Summary

How does Aptorum Group compare to Allarity Therapeutics?

Is ALLR or APM more profitable?

Do institutionals and insiders have more ownership in ALLR or APM?

Which has stronger valuation & earnings, ALLR or APM?

Which has more risk and volatility, ALLR or APM?

Do analysts prefer ALLR or APM?

Does the media favor ALLR or APM?

Summary

How does Aptorum Group compare to Rocket One Inc. Common Stock?

Do analysts rate APM or RKTO?

Do institutionals and insiders believe in APM or RKTO?

Which has more volatility & risk, APM or RKTO?

Which has better earnings and valuation, APM or RKTO?

Is APM or RKTO more profitable?

Does the media favor APM or RKTO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APM vs. The Competition

Aptorum Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools